Ala F. Nassar, PhD, is a faculty member at Yale University. He leads and executes ADME-Tox experiments supporting grant projects. He has served on numerous editorial boards and is the editor of the previous edition of Drug Metabolism Handbook: Concepts and Applications and Biotransformation and Metabolite Elucidation of Xenobiotics: Characterization and Identification.Paul F. Hollenberg, PhD, was the Maurice H. Seevers Professor and Chair of Pharmacology at the University of Michigan for more than 20 years. His research focused on the active sites of P450s and their catalytic function. He was cofounder and Associate Editor of Chemical Research in Toxicology and has served on numerous editorial boards and review panels.JoAnn Scatina, PhD has over 30 years of experience in Drug Metabolism and Preclinical Drug Development with leadership roles in both big pharma (Wyeth) and smaller biotech firms. She also provides expert drug development advice as a consultant to biotech and academic institutions.Soumen Kanti Manna, PhD, is an Associate Professor in the Biophysics and Structural Genomics Division of Saha Institute of Nuclear Physics, Kolkata. His doctoral work involved cytochrome P450 and other metalloproteins. His current research activities include unravelling of metabolic reprogramming associated with gene-environment interaction and cancer as well as RNA modification and biomarker discovery.Su Zeng, PhD, is a Professor and Director of Institute of Drug Metabolism and Pharmaceutical Analysis at College of Pharmaceutical Sciences, Zhejiang University. His research focuses on the regulation mechanism of drug ADME-Tox by using epigenetic models, transgenic cells expressing drug metabolizing enzymes, or transporters.